Organ transplantation is a safe treatment option for patients with human immunodeficiency virus (HIV) infection who need the operation, conclude researchers who reported their findings at the International Congress of the Transplantation Society. More important, they add, the immunosuppressive drugs used to control organ rejection seem to have little effect on HIV progression.
buy antibiotics canada

The advent of new treatments, such as highly active antiretroviral therapies (HAARTs), has meant that HIV patients who have liver disease are living longer— and thus are at risk for end-stage liver failure as a result of the infection or as a result of nephrotoxic drugs. The challenge, the researchers say, lies in finding the right balance between the antirejection drugs and the antiretroviral therapies. Oversuppression of the immune system might allow the HIV infection to worsen, but too low a dose puts the patient at risk for organ rejection.

Researchers at Hahnemann University Hospital in Philadelphia reported that 17 of 20 kidney transplant patients with HIV infection are alive one year after their study, with a very low to undetectable viral load. In one of the 20 patients, graft rejection developed because of an interaction with HAARTs.

In a French study, presented by a researcher from Paul Brousse Hospital in Villejuif, six patients with HIV infection and hepatitis C underwent liver transplantation. One died of liver failure, but the rest are alive more than a year later, with negligible levels of HIV viral load. However, interactions between the antirejection drug tacrolimus and protease inhibitors caused an acute rejection in one patient and toxic levels of tacrolimus in another.

In a study of seven liver and four kidney transplant patients at the University of Pittsburgh, the researchers observed profound drug interactions between tacrolimus and HAART that included a protease inhibitor. In contrast, regimens that included nucleoside reverse tran-scriptase inhibitors or non-nucleoside reverse transcriptase inhibitors resulted in less significant effects.
canadian pharmacy viagra

A study conducted at the University of California, San Francisco, found that viral loads have remained undetectable in four liver and 10 kidney transplant recipients. One patient died as a result of a rapid recurrence of the hepatitis virus. The researchers reported no evidence of significant HIV progression and no adverse effects of the virus on organ function.

Ximelagatran (Exantra®, AstraZeneca), an oral direct thrombin inhibitor, is an effective change of pace from warfarin, a commonly used anticoagulant, according to a 74-hospital study of 680 patients who had undergone total knee arthroplasty.

After seven to 12 days of treatment, the in­cidence of venous thromboembolism (measured by central adjudication) was 19% in pa­tients taking ximelagatran and 26% in those taking warfarin. On local assessment, the incidence was 25% with ximelagatran and 34% with warfarin. Major bleeding was rare, affecting only 1.7% of patients taking ximelagatran and 0.9% of those taking warfarin.

Unlike canadian warfarin, ximelagatran does not call for monitoring or dose adjustment. Drug interactions, diet, concomitant disease, and varying metabolisms all influence the utilization of warfarin, the researchers explain. Warfarin also has a delayed onset and does not achieve the target anticoagulant level until at least the third postoperative day—a problem in orthopedic surgery, when thrombosis may start on the first day. Ximelagatran is rapidly absorbed and converted to its active form, melagatran, which acts directly on throm-bin and is eliminated unmetabolized through the kidneys.

In fixed doses, ximelagatran produces predictable plasma melagatran concentrations and produces no known food or drug interactions, the researchers say, although plasma concentrations are influenced by renal function and the patient’s weight. Animal studies have indicated that ximelagatran has a wide therapeutic window and increases bleeding only slightly at therapeutic doses.

Because wound healing is a concern when antithrombotic therapy is used, the researchers also analyzed complications at the surgical site but observed no differences between the two groups.

Older women with severe asthma may be at greatest risk for undertreatment, say researchers who assessed adherence to the National Asthma Education and Prevention Program medication guidelines among participants in the Nurses’ Health Study. Of the 5,107 women who reported physician-diagnosed asthma, only 57% with mild asthma, 55% with moderate asthma, and 32% with severe asthma were taking medications as advised by the guidelines.

The figures seemed somewhat baffling, especially considering that the women in the study were health care providers them­selves. Psychosocial factors (e.g., marital status, social isolation), lack of insurance, and other possible influences could not completely account for the lack of adherence or the age gradient. Although the investigators had anticipated that low adherence among women with severe asthma would be a result of reluctance to use systemic corticosteroids, they found, in fact, that both those drugs and long-acting bronchodilators were underused.
discount drugs canda

The greatest increase in asthma-related mortality today is among older women. The researchers urge health care providers to make greater efforts to evaluate asthma severity and to step up therapy when indicated.

Colorectal cancer is the second leading cause of malignancy-related death in the U.S. It accounts for more than 10% to 15% of all cancer deaths. Every year about 150,000 new cases in the U.S. and about one million cases worldwide are diagnosed.

After a 46-day priority review, the Food and Drug Administration (FDA) approved oxaliplatin (Eloxatin, Sanofi-Synthelabo) as an injection to treat patients with col-orectal cancer that has recurred or progressed following six months of completion of first-line therapy with bolus infusional 5-fluorouracil (5-FU) and leu-covorin (LV) plus irinotecan (Camptosar, Pharmacia). Oxaliplatin will be administered in combination with 5-FU/LV. Approval was based on response rate and interim analysis showing improved time to radiographic progression.

At this time, no results have demonstrated a clinical benefit, such as improvement of disease-related symptoms or increased survival.

Xyrem, manufactured by Orphan Medical, has been approved for treating patients with narcolepsy who have episodes of cataplexy, a sudden loss of muscular control and weakness, usually triggered by emotions. The drug’s active ingredient is sodium oxybate, also known as gamma hydroxybutyrate (GHB).

Because of the abuse of GHB—it is used recreationally and in date rapes— distribution will be tightly controlled under Schedule III of the Controlled Substances Act. For the 20,000 to 50,000 people in the U.S. who suffer from narcolep-tic cataplexy, however, the news will be welcome, regardless of the restrictions. Cataplexy can cause a person with narcolepsy to collapse when the legs buckle. In clinical studies with 448 patients, the use of Xyrem, compared with placebo, reduced the number of cataplectic attacks.
canadian cialis

Xyrem can have serious side effects, including confusion, depression, difficulty breathing while sleeping, loss of consciousness, and abnormal thinking. Abuse of the drug can lead to dependence. For these reasons, and in light of the drug’s history, the FDA and the manufacturer have designed a comprehensive risk management program (the Xyrem Success Program). For instance, prescribers and patients will be able to get the drug only through a single centralized pharmacy.

About 30% of patients who have had my-ocardial infarction (MI) have a reoc-cluded artery within the first year of successful fibrinolysis, say researchers from the Interuniversity Cardiology Institute of the Netherlands. They found, however, that three months of heparin and coumarin therapy reduced reoc-clusion and recurrent events after successful thrombolysis by 45%.

The Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis (APRICOT)-2 trial included 308 patients who had a patent infarct-related artery 48 hours after fibrinolysis. Patients were randomly assigned to standard hepariniza-tion therapy and continuation of aspirin alone or to three months of aspirin therapy with moderate-intensity coumarin as well as continued heparin.
canadian antibiotics

At three months, only 15% of patients taking coumarin plus aspirin experienced reocclusion compared to 28% taking aspirin alone. Only 2% had a new MI, compared to 8% taking aspirin. Only 13% needed revascularization, compared with 31% receiving aspirin. The reocclusion rate for patients taking fibrin-specific lyt-ics was 17%, versus 24% for those taking non–fibrin-specific agents. Bleeding was infrequent.

Recent studies have suggested that an-giotensin-converting enzyme (ACE) in­hibitors do not work as well in African-American patients as in white patients. Researchers from the University of Texas and Loyola University, however, take issue with those findings.

Based on their own retrospective analysis of data from 403 African-American and 3,651 white participants in the Studies of Left Ventricular Dysfunction Prevention Trial, they say that ethnicity does not influence the effectiveness of at least one ACE inhibitor, enalapril.

The researchers were concerned that the publicity surrounding ACE inhibitors and race might dissuade clinicians from using a life-saving drug for their black patients. However, in their study, they found that canadian enalapril worked equally well in both groups, both in reducing the need for medications for heart failure symptoms and reducing the risk of developing heart failure or dying from it.

That’s not to say that blacks are not still at higher risk for symptomatic heart failure than whites. Studies have shown that even after adjusting for differences in severity of symptoms, comorbidities, and socioeconomic factors, blacks have a substantially greater absolute risk for progression from asymptomatic LVD to symptomatic HF, the researchers note. And, despite the comparable relative reduction in risk associated with enalapril in both whites and blacks, the differences in the baseline magnitude of risk was such that blacks randomized to enalapril remained at higher risk than whites randomized to placebo. The differences between black and white patients in the risk of progression of ALVD persisted after the researchers adjusted for potential con-founders such as ejection fraction, NYHA class, serum sodium, and etiology of LV dysfunction.

The researchers interpret their findings as suggesting either that residual confounding exists or that there are differences in the natural history of ALVD in blacks and whites.